Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285557 · ClinicalTrials.gov registry record · Phase 3
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
A Phase 3 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 361
- Enrollment target
NCT01285557 is a Phase 3 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 361 participants.
The verdict
NCT01285557, a Phase 3 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 361 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.
Interventions
- DRUG S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)
- DRUG Fluorouracil/cisplatin (control arm)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2011-04-14 |
| Est. Completion | 2014-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285557
The ClinicalTrials.gov registry entry for NCT01285557 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) is the first listed.
NCT01285557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285557 about?
NCT01285557 is a clinical study titled "Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial". The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.
What is the current status of trial NCT01285557?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 361 participants. The study started on 2011-04-14. Estimated completion is 2014-08-15.
What interventions are being tested in trial NCT01285557?
The interventions under investigation include: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) (DRUG), Fluorouracil/cisplatin (control arm) (DRUG).
Who is sponsoring clinical trial NCT01285557?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.